Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Sep 15, 2021; 13(9): 1062-1072
Published online Sep 15, 2021. doi: 10.4251/wjgo.v13.i9.1062
Published online Sep 15, 2021. doi: 10.4251/wjgo.v13.i9.1062
Ref. | n | Survival |
Hermanek et al[56], 2000 | 86 | MS 4.7 mo (1.8-12.2) |
Wiig et al[57], 2002 | 24 | OS 5 yr 0% |
Treiber et al[58], 2004 | 20 | CL 3 yr 29% |
Landmann et al[59], 2005 | 19 | MS < 12 mo OS 5 yr 0% |
Dresen et al[60], 2008 | 36 | OS 3 yr 24.1% |
Rahbari et al[21], 2011 | 13 | MS 23 mo 23.1% |
Bhangu et al[61], 2012 | 163 | MS 17 mo |
Roeder et al[62], 2012 | 29 | OS 3 yr 35%, LC 3 yr 18% |
Haddock et al[63], 2017 | 158 | OS 5 yr 16% |
Holman et al[64], 2017 | 125 | OS 3 and 5 yr 37% and 17% |
PelvEx Collaborative et al[65], 2019 | 26 | OS 5 yr 8.1% |
Westberg et al[66], 2019 | 50 | OS 3 yr 8%, OS 5 yr 4% |
- Citation: Pérez Lara FJ, Hebrero Jimenez ML, Moya Donoso FJ, Hernández Gonzalez JM, Pitarch Martinez M, Prieto-Puga Arjona T. Review of incomplete macroscopic resections (R2) in rectal cancer: Treatment, prognosis and future perspectives. World J Gastrointest Oncol 2021; 13(9): 1062-1072
- URL: https://www.wjgnet.com/1948-5204/full/v13/i9/1062.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i9.1062